Vol 8, No 2 (2022)
Review paper
Published online: 2022-03-24
Page views 2431
Article views/downloads 42
Get Citation

Connect on Social Media

Connect on Social Media

Sweet’s syndrome — etiopathogenesis, clinical presentation, diagnosis, treatment

Anna Czaplicka1, Jakub Biliński1, Klaudia Dopytalska1, Irena Walecka1
Forum Dermatologicum 2022;8(2):63-68.

Abstract

Sweet’s syndrome is a rare inflammatory disorder belonging to the group of neutrophilic dermatoses. It is characterized by a sudden onset of skin lesions such as papules, nodules, plaques, accompanied by fever and leukocytosis. The syndrome is typically classified into the following subtypes: classical, malignancy-associated and drug-induced. The etiopathogenesis of Sweet’s syndrome remains unclear. The syndrome is sometimes preceded by infection of the respiratory system, digestive system, vaccination or coexists with neoplastic disease, inflammatory disease or pregnancy. A characteristic feature of Sweet’s syndrome is a good response to systemic treatment with glucocorticosteroids and a rapid resolution of the lesions. On average, one third of patients have recurrent lesions.

Article available in PDF format

Add to basket: 49.00 PLN

Aready have access?

References

  1. Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol. 1964; 76: 349–356.
  2. Villarreal-Villarreal CD, Ocampo-Candiani J, Villarreal-Martínez A. Sweet Syndrome: A Review and Update. Actas Dermosifiliogr. 2016; 107(5): 369–378.
  3. Nelson CA, Stephen S, Ashchyan HJ, et al. Neutrophilic dermatoses: Pathogenesis, Sweet syndrome, neutrophilic eccrine hidradenitis, and Behçet disease. J Am Acad Dermatol. 2018; 79(6): 987–1006.
  4. Heath MS, Ortega-Loayza AG. Insights Into the Pathogenesis of Sweet's Syndrome. Front Immunol. 2019; 10: 414.
  5. Marzano AV, Ortega-Loayza AG, Heath M, et al. Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. Front Immunol. 2019; 10: 1059.
  6. Nelson CA, Noe MH, McMahon CM, et al. Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018; 78(2): 303–309.e4.
  7. Kumar G, Bernstein JM, Waibel JS, et al. Sweet's syndrome associated with sargramostim (granulocyte-macrophage colony stimulating factor) treatment. Am J Hematol. 2004; 76(3): 283–285.
  8. Nelis S, Azerad MA, Drowart A, et al. [Sweet's syndrome induced by pegfilgrastim during a myelodysplastic syndrome AREB2: A case report]. Rev Med Interne. 2019; 40(4): 258–261.
  9. Pérez-Feal P, Pita da Veiga G, Moreiras-Arias N, et al. Sweet's syndrome triggered by ultraviolet light. Photodiagnosis Photodyn Ther. 2021; 34: 102258.
  10. Ramsey AL, Wallace WD, Abtin F, et al. Sweet's Syndrome: A First in Human Lung Transplantation. Chest. 2021; 160(2): e173–e176.
  11. Sechi A, Pierobon E, Pezzolo E, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. Clin Exp Dermatol. 2022; 47(2): 437–440.
  12. Darrigade AS, Théophile H, Sanchez-Pena P, et al. Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine. Allergy. 2021; 76(10): 3194–3196.
  13. von den Driesch P, von den Driesch P, Dannecker GE, et al. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994; 31: 535–556.
  14. Walker DC, Cohen PR. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol. 1996; 34(5 Pt 2): 918–923.
  15. Shahid Z, Kalayanamitra R, Patel R, et al. Refractory Sweet Syndrome Treated with Anakinra. Cureus. 2019; 11(4): e4536.